- Reviews (0)
|Antigen/Gene or Protein Targets||Human derived carcinomas of breast, ovarian and renal origin|
|On Target IC50||IC50 values for MCF-7 and MDA468 cells are 40 nM and 158 nM, respectively|
|Molecular Weight (g/mol)||459.41|
|In vivo applications||Active against breast, ovarian and renal carcinomas. Taken up into sensitive cells followed by aryl hydrocarbon receptor binding and translocation into the nucleus. Requires metabolic activation by cytochrome P450 to generate cytotoxic species.|
|In vitro applications||Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells.|
The Antitumoral Phortress compound is a potential anticancer agent for treatment of human breast carcinoma. Phortress is highly selective for susceptible cancer cells because of its mechanism of action. Following the release of 5F 203 from Phortress, it activates AhR signalling and causes induction of cytochrome P450 activity, which metabolically bioactivates 5F 203 to a cytotoxic species at the tumour site.
Phortress (the dihydrochloride salt of the lysylamide prodrug of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203)) is an experimental antitumour agent with potent and selective activity against human-derived carcinomas of breast, ovarian and renal origin
The mechanism of action of Phortress is distinct from all classes of chemotherapeutic agents currently in the clinic, and involves metabolic activation by cytochrome P450 (CYP) 1A1 to electrophilic species, which generate DNA adducts in sensitive tumours only.
|Notes||Compound available for screening or similar studies. For larger quantities (>20mg) please contact Ximbio.|
Have you used this reagent? Share your experience by submitting a review and help your fellow scientists.Review this reagent